Assessing Spns2-dependent S1P Transport as a Prospective Therapeutic Target
K. R. Lynch, Y. Kharel, T. Huang, K. Dunnavant, D. Foster, W. Santos, W. Xu, A. Gaultier, A. Merchak, N. Leitinger, C. Pavelec, S. B. Abbott, G. M. Souza, K. T. Nimchuk, J.-B. Shin, , Z. J. Juskiewicz
This study evaluates a novel S1P transport blocker, SLF80821178, showing efficacy in multiple sclerosis without the cardiac side effects of SRMs, but with less lymphopenia and unchanged lymph S1P levels.
bioRxiv · Mar 26, 2024 · PreprintPharmacology & Toxicology